Back to mobile site

Raymond James looks for further durability in BMY's (BMY) MountainTAP-30 trial

March 16, 2026 4:28 PM EDT Send to a Friend
Raymond James analyst Sean McCutcheon reiterated a Market Perform rating on Bristol-Myers Squibb Co. (NYSE: BMY)The analyst commented, "Monday, at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login